ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The US Department of Defense has awarded Evotec a contract of up to $49.9 million to quickly develop monoclonal antibodies against plague. Plague is a bacterial disease that still infects people in parts of Africa, Asia, and the western US, according to the US Centers for Disease Control and Prevention. The firm’s drug services Just–Evotec Biologics unit will be responsible for development through Phase 1 first-in-human trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter